on ABIVAX (EPA:ABVX)
ABIVAX: Update of share capital and voting rights
On March 27, 2025, ABIVAX, a company listed on Euronext Paris, communicated the details relating to its share capital and voting rights as of February 28, 2025. The company's share capital is set at €634,187.49, spread over 63,383,293 shares.
ABIVAX announces that the total number of voting rights, both theoretical and exercisable, amounts to 71,083,363. Theoretical voting rights serve as a reference for threshold crossings in accordance with AMF regulations.
The company, which specializes in developing therapeutic treatments, continues to focus on chronic inflammatory diseases. Its lead candidate, obefazimod, is in Phase 3 development for the treatment of ulcerative colitis.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ABIVAX news